http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103483422-B
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bceed6bebc0cc13575ef9690aa72e1c0 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-08 |
| filingDate | 2013-09-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2015-06-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a89cc7ca7ad3f51a0322ac3854cbde52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8c339b93980e06b2a06a668a5d56e3a1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_768d8e17c692970394bcaf4c203f9fc7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3edf602808230124b8dc984f393293b5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d5807a75e4af912738153c48d166d590 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8c2ede3e031a8b2a9baae55db471e533 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d721ffcf82ca440c3b5c58f32bed383e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_05ad87842cfa311509ef166deb568a2b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0ede9c55a2db734e6de96d55ab2825e4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cb666a85541059800b4a09dcf3cdb3cd |
| publicationDate | 2015-06-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-103483422-B |
| titleOfInvention | NGR polypeptide radiopharmaceutical as well as preparation method and application thereof |
| abstract | The invention relates to an NGR (asparagine-glycine-arginine) polypeptide radiopharmaceutical as well as a preparation method and application thereof. The currently reported radionuclide-labeled NGR-containing sequence has a higher liver uptake rate. The NGR polypeptide radiopharmaceutical is formed with the preparation method comprising the steps as follows: monomers and dimmers of an NGR cyclopeptide are connected with a chelating agent NOTA to form a coordination compound, and the coordination compound finally forms the radiopharmaceutical through chelation of the NOTA (disodium edta) and radionuclides; the targeting action of the NGR polypeptide enables the radiopharmaceutical to be concentrated to a tumor part, and the nuclear medicine positron emission computerized tomography technology is utilized to image the CD13 positive tumor, so as to achieve the purpose of specific diagnosis. According to the invention, since the NOTA is used as a bifunctional chelator to be chelated with the radionuclides, and the p-SCN-Bn is used as a coupling agent to enable the NGR to be directly connected to a carbon skeleton of the NOTA, the situation that the coordination of the carboxyl oxygen atoms and the radionuclides is influenced by connection of the coupling agent and the NOTA carboxyl is avoided; seen from the metabolism in vivo, the radiopharmaceutical can be quickly metabolized through the kidney after being injected into the body, and the liver uptake rate is lower. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3882257-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021186071-A1 |
| priorityDate | 2013-09-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 71.